Bionano Genomics Inc. (BNGO)

The total asset value of Bionano Genomics Inc. (BNGO) stood at $ 330 Mln as on 31-Mar-23

The share price of Bionano Genomics Inc. (BNGO) is $1.51 (NASDAQ) as of 28-Nov-2023 16:00 EST. Bionano Genomics Inc. (BNGO) has given a return of -32.4% in the last 3 years.

Bionano Genomics Inc. (BNGO) has a market capitalisation of $ 264 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of Bionano Genomics Inc. (BNGO) is 2.23 times as on 02-Jun-2023, a -0.24% premium to its peers’ median range of 2.95 times.

Since, TTM earnings of Bionano Genomics Inc. (BNGO) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bionano Genomics Inc. (BNGO) and enter the required number of quantities and click on buy to purchase the shares of Bionano Genomics Inc. (BNGO).

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

The CEO & director of Dr. Robert Erik Holmlin M.B.A., Ph.D.. is Bionano Genomics Inc. (BNGO), and CFO & Sr. VP is Mr. Mark Oldakowski.

The promoters of Bionano Genomics Inc. (BNGO) have pledged 0% of the total equity as on Dec-22.

Some of the close peers are:

No, TTM profit after tax of Bionano Genomics Inc. (BNGO) was $-140 Mln.